Select Bibliography

Filter by any of these (after searching):

CALGB-40101

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 18 items

A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101

Baldwin, R. Michael , Owzar, Kouros , Zembutsu, Hitoshi ... - - Clin Cancer Res - 2012

Manuscript - Secondary-not-in-original - Primary - PPP - CALGB-40101

Age and the Risk of Paclitaxel‐Induced Neuropathy in Women with Early‐Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101

Barginear, Myra , Dueck, Amylou C. , Allred, Jacob B. ... - - Oncologist - 2019

Manuscript - Primary - Primary - Older Adult - A151411 , CALGB-40101 , CALGB-70301

Polygenic Inheritance of Paclitaxel-Induced Sensory Peripheral Neuropathy Driven by Axon Outgrowth Gene Sets in CALGB 40101 (Alliance)

Chhibber, Aparna , Mefford, Joel , Stahl, Eli A. ... - - Pharmacogenomics J - 2014

Manuscript - Secondary-not-in-original - Primary - PPP - CALGB-40101

Meta-analysis identifies variants in S1PR1 associated with microtubule targeting agent-induced sensory peripheral neuropathy CALGB 40101 and 40502 (Alliance)

Chua, Katherina C. , Ho, Carol , Mushiroda, Tasei , Jiang, Chen ... - ASCPT - Clinical Pharmacology & Therapeutics - 2018

Abstract - Secondary-not-in-original - Meta-Analysis - Breast - CALGB-40101 , CALGB-40502

Genome-Wide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy

Chua, Katherina C. , Xiong, Chenling , Ho, Carol , Mushiroda, Taisei ... - - Clin Pharmacol Ther - 2020

Manuscript - Secondary-not-in-original - Meta-Analysis - PPP - CALGB-40101 , CALGB-40502

Is there a role for older-patient-specific trials? a pooled analysis of 2277 older patients in adjuvant breast cancer trials (Alliance A151715)

Dao, Dyda , Zelma, Tyler , Jatoi, Aminah , Freedman, Rachel ... - ASCO - J Clin Oncol - 2018

Abstract - Primary - Primary - Older Adult - A151715 , C8541 , CALGB-40101 , CALGB-49907 , CALGB-9344 , CALGB-9741 , N89-30-52 , N9831

Participation in cancer pharmacogenomic studies in 8,456 patients registered to Cancer and Leukemia Group B (Alliance) clinical trials

Dressler, L. G. , Deal, A. M. , Watson, D. , Hollis, D. , Owzar, K. ... - ASCO - J Clin Oncol - 2013

Abstract - Secondary-not-in-original - Meta-Analysis - Health Outcomes - CALGB-40101 , CALGB-50303 , CALGB-80203 , CALGB-80303 , CALGB-80405 , CALGB-90401

Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance)

Dressler, Lynn G. , Deal, Allison M. , Owzar, Kouros ... - - J Natl Cancer Inst - 2015

Manuscript - Secondary-not-in-original - Meta-Analysis - Health Outcomes - CALGB-40101 , CALGB-50303 , CALGB-80101 , CALGB-80203 , CALGB-80303 , CALGB-80405 , CALGB-90401

Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527

Freedman, Rachel A. , Foster, Jared C. , Seisler, Drew K. ... - - J Clin Oncol - 2017

Manuscript - Primary - Primary - Older Adult - A151527 , ACOSOG-Z1031 , ACOSOG-Z1041 , C8541 , C9344 , C9741 , CALGB-40101 , CALGB-40302 , CALGB-40502 , CALGB-40503 , CALGB-40601 , CALGB-40603 , CALGB-49907 , CALGB-9342 , CALGB-9840 , N89-30-52 , N9831

Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511)

Freedman, Rachel A. , Seisler, D. K. , Foster, J. C. , Sloan, J. A. ... - - Breast Cancer Res Treat - 2017

Manuscript - Primary - Primary - Older Adult - A151511 , CALGB-40101 , CALGB-49907 , CALGB-9344 , CALGB-9741

Accrual of Older Breast Cancer Patients to Alliance Systemic Therapy Protocols over Time: Alliance A151527

Freedman, Rachel A , Seisler, Drew K. , Foster, Jared C. ... - ASCO - J Clin Oncol - 2016

Abstract - Primary - Primary - Older Adult - A151527 , ACOSOG-Z1031 , ACOSOG-Z1041 , C8541 , C9344 , C9741 , CALGB-40101 , CALGB-40302 , CALGB-40502 , CALGB-40503 , CALGB-40601 , CALGB-40603 , CALGB-49907 , CALGB-9342 , CALGB-9840 , N89-30-52 , N9831

Inherited genetic variation in EPHA5, FGD4 and NRDG1 and paclitaxel (P) induced peripheral neuropathy (PN): Results from a genome-wide association study (GWAS) in CALGB 40101

Kroetz, D. L. , Baldwin, R. , Owzar, K. , Jiang, C. , Zembutsu, H. ... - ASCO - J Clin Oncol - 2010

Abstract - Primary - Primary - PPP - C60202 , CALGB-40101

Role of age, BMI, and tumor subtype in racial/ethnic disparities in breast cancer survival: A pooled analysis of four Alliance adjuvant clinical trials.

Lipsyc-Sharf, Marla , Ballman, Karla V. , Campbell, Jordan D. ... - AACR - Cancer Res - 2022

Abstract - Secondary-not-in-original - Meta-Analysis - Breast - CALGB-40101 , CALGB-49907 , CALGB-9741 , NCCTG-N9831

Six cycles of Doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: cancer and leukemia group B 40101

Shulman, L. N. , Cirrincione, C. T. , Berry, D. A. , Becker, H. P. ... - - J Clin Oncol - 2012

Manuscript - Primary - Primary - Breast - CALGB-40101

Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes: CALGB 40101 A 2x2 Factorial Phase III Trial: First Results Comparing 4 vs 6 Cycles of Therapy.

Shulman, L. N. , Cirrincione, C. T. , Berry, D. A. , Becker, H. P. ... - SABCS - - 2010

Abstract - Primary - Preliminary - Breast - CALGB-40101

Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)

Shulman, Lawrence N. , Berry, Donald A. , Cirrincione, Constance T. ... - - J Clin Oncol - 2014

Manuscript - Secondary - Primary - Breast - CALGB-40101

Genome-Wide Meta-Analyses Identifies Novel Taxane-Induced Peripheral Neuropathy Associated Loci

Sucheston-Campbell, L E , Clay-Gilmour, A I , Barlow, W E , Budd, G T ... - - Pharmacogenet Genomics - 2018

Manuscript - Secondary-not-in-original - Meta-Analysis - PPP - CALGB-40101 , S0221

Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of paclitaxel-induced sensory peripheral neuropathy

Wheeler, Heather E. , Gamazon, Eric R. , Wing, Claudia ... - - Clin Cancer Res - 2013

Manuscript - Secondary-not-in-original - Primary - PPP - CALGB-40101